by Truveta Research | Apr 9, 2026 | Research
Estrogen-based hormone replacement therapy (HRT) prescribing more than doubled from 2018 to 2026. The largest increases were seen in patches and vaginal creams, with patch use more than tripling and vaginal cream use increasing more than fourfold. The rates of women...
by Truveta staff | Apr 7, 2026 | Research
Four studies using Truveta Data examined real-world outcomes across diverse urology populations, spanning medical therapy, stone disease, oncology, and men’s health. The analyses identified differences in treatment patterns, safety, and outcomes not captured in...
by Truveta staff | Apr 2, 2026 | Research
A new study from University of Michigan using Truveta Data analyzed cervical cancer screening among more than 2.4 million eligible individuals across health systems in 34 states. Family medicine and internal medicine clinicians provided the majority of cervical cancer...
by Truveta staff | Mar 31, 2026 | Research
Schizophrenia treatment is rarely linear. Patients may discontinue therapy, add a medication, need escalating care, or cycle through periods of instability that carry real clinical and economic consequences. In a systematic review of US real-world oral antipsychotic...
by Truveta staff | Mar 26, 2026 | Research
A newly published study from researchers at Lilly found greater weight loss with tirzepatide than semaglutide among adults treated for obesity in routine clinical practice. Published in the Journal of Endocrinological Investigation, the analysis examined outcomes...
by Truveta staff | Mar 24, 2026 | Research
Seizure frequency is one of the most important outcomes in epilepsy research, but it often lives in unstructured clinical notes rather than standard EHR fields. In a recent Neurology abstract, researchers from SK Life Science and Truveta show how the Truveta Language...
